Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry.
Sign Up to like & getrecommendations! Published in 2020 at "Annales de cardiologie et d'angeiologie"
DOI: 10.1016/j.ancard.2020.07.002
Abstract: BACKGROUND Following the publication of the COMPASS trial, the European Medicines Agency has approved a regimen of combination of rivaroxaban 2.5mg twice daily and a daily dose of 75-100mg acetylsalicylic acid (ASA) for patients with… read more here.
Keywords: reach registry; clinical characteristics; compass; france ... See more keywords
Examining the applicability of SPRINT in patients with subclinical or established atherothrombotic disease: A REACH registry analysis.
Sign Up to like & getrecommendations! Published in 2017 at "International journal of cardiology"
DOI: 10.1016/j.ijcard.2017.05.104
Abstract: BACKGROUND The optimal blood pressure (BP) target to reduce the risk of cardiovascular (CV) events remains uncertain, especially in patients with coronary artery disease (CAD). Results from the Systolic Blood Pressure Intervention Trial (SPRINT) suggest… read more here.
Keywords: sprint; reach registry; systolic 120mmhg; applicability sprint ... See more keywords